CoreCap Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

CoreCap Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.2K	Buy	2,967 +1,682	+131%	+$3.05K	﹤0.01%	2368
2026 Q2	$4.29K	Buy	+1,285	New	+$6.1K	﹤0.01%	2319

Other funds holding CVKD

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors's CVKD Position: Q3 2026 in Review

CoreCap Advisors increased its Cadrenal Therapeutics (CVKD) stake by 131% in Q3 2026, buying an estimated $3.05K and bringing the position to 2,967 shares worth $3.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

CoreCap Advisors first reported a position in CVKD in Q2 2026 and has held it in 2 quarters since. The position peaked at $4.29K in Q2 2026. 5 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

CoreCap Advisors held 2,967 shares of Cadrenal Therapeutics worth $3.2K as of Q3 2026.
CoreCap Advisors bought 1,682 Cadrenal Therapeutics shares in Q3 2026, an estimated $3.05K.
Cadrenal Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2368 holding.
CoreCap Advisors first reported a position in Cadrenal Therapeutics in Q2 2026 and has held it in 2 quarters since.
CoreCap Advisors's Cadrenal Therapeutics position peaked at $4.29K in Q2 2026.
5 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.